Blue water vaccines announces exploration of its virus-like particle (vlp) platform for use in monkeypox vaccine candidate

Cincinnati, aug. 17, 2022 (globe newswire) -- blue water vaccines inc. (“bwv” or “blue water vaccines” or “the company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion (s&p) virus-like particle (vlp) platform.
BWV Ratings Summary
BWV Quant Ranking